drugset
Drugs / sacubitril/valsartan
last change Mar 2020 re-read 2 minutes ago

sacubitril/valsartan

also known as LCZ696
Developed for
hypertensive disorder
Investigated by
Novartis Pharmaceuticals

Trials 1 · a red edge is where a trial was stopped

today NCT01870739 · Ph 2
20142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT01870739 Oct 2013 → Jun 2015 hypertensive disorder Novartis Pharmaceuticals Completed No outcome recorded

Press releases naming this drug 4 releases

DateIssuerRelease
2020-03-02 Otsuka Pharmaceutical Development & Commercialization, Inc. Otsuka enters into co-promotion agreement for angiotensin receptor neprilysin inhibitor (ARNI) LCZ696 in Japan otsuka.co.jp ↗
2018-08-25 Novartis Pharmaceuticals Novartis announces new data that show Entresto® (sacubitril/valsartan) can be initiated early & safely in hospitalized patients after an acute heart failure episode novartis.com ↗
2015-07-07 Novartis Pharmaceuticals Novartis' new heart failure medicine LCZ696, now called Entresto(TM), approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization novartis.com ↗
2015-02-13 Novartis Pharmaceuticals Novartis' heart failure medicine LCZ696 granted FDA priority review novartis.com ↗

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as sacubitril/valsartan ClinicalTrials.gov intervention name — accepted as the source's own label NCT01870739 ↗
Known as LCZ696 “sacubitril/valsartan (LCZ696)” NCT01870739 ↗